1. Home
  2. SPWRW vs ABVC Comparison

SPWRW vs ABVC Comparison

Compare SPWRW & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPWRW
  • ABVC
  • Stock Information
  • Founded
  • SPWRW N/A
  • ABVC 2015
  • Country
  • SPWRW United States
  • ABVC United States
  • Employees
  • SPWRW N/A
  • ABVC N/A
  • Industry
  • SPWRW Semiconductors
  • ABVC Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPWRW Technology
  • ABVC Health Care
  • Exchange
  • SPWRW Nasdaq
  • ABVC Nasdaq
  • Market Cap
  • SPWRW 15.5M
  • ABVC 16.7M
  • IPO Year
  • SPWRW N/A
  • ABVC N/A
  • Fundamental
  • Price
  • SPWRW $0.20
  • ABVC $1.21
  • Analyst Decision
  • SPWRW
  • ABVC
  • Analyst Count
  • SPWRW 0
  • ABVC 0
  • Target Price
  • SPWRW N/A
  • ABVC N/A
  • AVG Volume (30 Days)
  • SPWRW N/A
  • ABVC 203.5K
  • Earning Date
  • SPWRW N/A
  • ABVC 04-30-2025
  • Dividend Yield
  • SPWRW N/A
  • ABVC N/A
  • EPS Growth
  • SPWRW N/A
  • ABVC N/A
  • EPS
  • SPWRW N/A
  • ABVC N/A
  • Revenue
  • SPWRW N/A
  • ABVC $508,383.00
  • Revenue This Year
  • SPWRW N/A
  • ABVC $735.18
  • Revenue Next Year
  • SPWRW N/A
  • ABVC N/A
  • P/E Ratio
  • SPWRW N/A
  • ABVC N/A
  • Revenue Growth
  • SPWRW N/A
  • ABVC 1904.43
  • 52 Week Low
  • SPWRW N/A
  • ABVC $0.40
  • 52 Week High
  • SPWRW N/A
  • ABVC $1.40
  • Technical
  • Relative Strength Index (RSI)
  • SPWRW N/A
  • ABVC 62.38
  • Support Level
  • SPWRW N/A
  • ABVC $1.01
  • Resistance Level
  • SPWRW N/A
  • ABVC $1.36
  • Average True Range (ATR)
  • SPWRW 0.00
  • ABVC 0.10
  • MACD
  • SPWRW 0.00
  • ABVC 0.02
  • Stochastic Oscillator
  • SPWRW 0.00
  • ABVC 72.92

About ABVC ABVC BioPharma Inc.

ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

Share on Social Networks: